Research Analysts Issue Forecasts for BHST Q2 Earnings

BioHarvest Sciences Inc. (NASDAQ:BHST) – Equities researchers at HC Wainwright dropped their Q2 2025 EPS estimates for BioHarvest Sciences in a note issued to investors on Monday, May 19th. HC Wainwright analyst A. Dayal now expects that the company will post earnings of ($0.11) per share for the quarter, down from their prior forecast of ($0.10). HC Wainwright has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for BioHarvest Sciences’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for BioHarvest Sciences’ Q3 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.30) EPS.

BioHarvest Sciences (NASDAQ:BHST) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. The business had revenue of $7.64 million for the quarter, compared to analyst estimates of $8.93 million.

Separately, Craig Hallum assumed coverage on shares of BioHarvest Sciences in a research report on Monday, May 5th. They set a “buy” rating and a $15.00 target price on the stock.

BioHarvest Sciences Trading Down 3.9%

NASDAQ BHST opened at $6.24 on Wednesday. The stock’s fifty day moving average price is $6.15. BioHarvest Sciences has a 52 week low of $6.24 and a 52 week high of $7.38. The firm has a market capitalization of $102.49 million, a PE ratio of -5.00 and a beta of 0.80.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Magnus Financial Group LLC lifted its position in shares of BioHarvest Sciences by 105.0% during the first quarter. Magnus Financial Group LLC now owns 71,733 shares of the company’s stock worth $444,000 after purchasing an additional 36,733 shares in the last quarter. True North Advisors LLC raised its holdings in BioHarvest Sciences by 7.6% in the first quarter. True North Advisors LLC now owns 44,391 shares of the company’s stock valued at $275,000 after acquiring an additional 3,120 shares in the last quarter. Finally, TD Waterhouse Canada Inc. acquired a new stake in BioHarvest Sciences in the fourth quarter valued at $69,000.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.